Fusion Antibodies and Queen’s University Belfast Awarded a £453,000 Grant from Invest Northern Ireland

VERITAS Vision System Is Introduced by Johnson & Johnson

The company will offer live demos of the new system in a wet lab at the Johnson & Johnson booth (#2813) this weekend at the 2021 American Society of Cataract and Refractive Surgery and American Society of Ophthalmic Administrators Annual Meeting.

GenesisCare Orders 27 Elekta Flexitron Treatment Devices

"GenesisCare continues to demonstrate its commitment to improving patient outcomes worldwide and Elekta is delighted to play a vital partnering role to achieve this mission," said Gustaf Salford, Elekta's President and CEO.

FoodMarble AIRE Shown to Exceed the Performance of ‘Gold Standard’ SIBO Testing in Clinical Trial

SIBO is a very common disorder where there are excessive bacteria present in the small intestine. The true prevalence of SIBO in the general population is largely unknown, with some studies estimating its occurrence in up to 15% of healthy individuals. It is also largely associated with many other common clinical conditions, including irritable bowel syndrome, where 40-80% of IBS patients have SIBO.

December 3, 2020

Fusion Antibodies, pre-clinical antibody discovery, engineering and supply experts, and Queen’s University Belfast, the leader in innovation and impact, have been awarded a £453,000 grant from Invest Northern Ireland to further expand their COVID-19 targeted research and development efforts.

Fusion Antibodies reports within the framework of their Northern Ireland Coronavirus Antibody Development Alliance (NICADA), the two organizations will use the funds to accelerate the discovery of novel therapeutic and diagnostic antibodies with validated anti-infective properties against COVID-19.
“The COVID-19 pandemic has prompted rising demand for select antibodies, specifically engineered to neutralize the SARS-CoV-2 virus, while also facilitating diagnostic testing,” said Dr. Paul Kerr, CEO at Fusion Antibodies. “Since the early stages of the pandemic, Fusion Antibodies has been committed to discovering new therapeutic and diagnostic approaches to help in the fight against this growing threat. The new funding is set to further strengthen NICADA, enabling us to provide the global biopharmaceutical and clinical diagnostics communities with the necessary tools they need to mount an effective COVID-19 response.”
Building on strong scientific expertise and application know-how, Fusion Antibodies and Queen’s University Belfast will be using the Invest Northern Ireland grant to pioneer a new commercially-competitive antibody development platform. The novel technology will be capable of simultaneously creating COVID-19 antibodies of unparalleled quality: humanized, affinity- and selectivity-matured, stability- and developability-optimized. These state-of-the-art antibodies will have a SARS-CoV-2 virus neutralization ability, while also aiding diagnostic testing efforts.
“At NICADA, we envisage a breakthrough antibody-drug therapy targeting SARS-CoV-2 directly,” said Ultan Power, Professor of Molecular Virology at The Wellcome-Wolfson Institute for Experimental Medicine, Queen’s University Belfast. “The Invest Northern Ireland grant will enable us to exploit our SARS-CoV-2 virology expertise to help generate a new antibody development platform that will allow us to realize this vision, helping us to discover new drug targets to combat the devastating COVID-19 disease.”
In anticipation of the new funding, Fusion Antibodies has already designed and expressed a panel of unique protein antigens for use in discovery platforms in the search for a neutralising therapeutic antibody against SARS-CoV-2. The panel of proteins have shown excellent profiles in terms of activity and scalability.
More information about the COVID-19 related work at Fusion Antibodies can be found here.
spot_img

DON'T MISS

Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.